Gilead first-quarter profit doubles on strong hepatitis C drug sales

April 30, 2015 9:01 PM

20 0

LOS ANGELES (Reuters) - Gilead Sciences Inc said on Thursday its quarterly net profit nearly doubled, driven by sales of its novel hepatitis C drugs, as it topped Wall Street estimates.

The results and an increase in the company's full-year sales outlook sent shares of Gilead, which fell 1.8 percent in regular trading, up 2.6 percent at $103.09 after hours.

Read more

To category page